Vira Aulia Kusuma Wardani

Vira Aulia Kusuma Wardani

Auto-generated profile, based on publicly available information

Vira Aulia Kusuma Wardani

Faculty of Medicine, Hang Tuah University, Surabaya, Indonesia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Open Access Macedonian Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
AAArga Setyo Adji
Arga Setyo Adji
JWJordan Steven Widjaja
Jordan Steven Widjaja
VWVira Aulia Kusuma Wardani
Vira Aulia Kusuma Wardani
AMAlvian Habib Muhammad
Alvian Habib Muhammad
FHFitri Handajani
Fitri Handajani
FRFirman Suryadi Rahman
Firman Suryadi Rahman
A Review of CRISPR Cas9 for Alzheimer’s Disease: Treatment Strategies and Could target APOE e4, APP, and PSEN-1 Gene using CRISPR cas9 Prevent the Patient from Alzheimer’s Disease? BACKGROUND: Alzheimer’s disease is a neurodegenerative disorder characterized by the formation of β-amyloid plaques and neurofibrillary tangles from hyperphosphorylated tau. Several studies suggest that targeting the deletion of the APOE e4, PSEN-1, and APP will reduce tau phosphorylation and Aβ protein accumulation, a crucial hypothesis for the causation of Alzheimer’s disease. APOE e4, PSEN-1, and APP with genome editing Clustered Regular interspersed Short Palindromic Repeats-CRISPR-related (CRISPR/Cas9) are thought to have therapeutic promise for Alzheimer’s disease.AIM: The purpose of this study was to determine whether targeting APOE e4, PSEN-1, and APP using CRISPR/Cas9 is an effective therapeutic and whether it has a long-term effect on Alzheimer’s disease.METHODS: The method used in this study summarized articles by examining the titles and abstracts of specific specified keywords. In this situation, the author picked the title and abstract that matched PubMed, Google Scholar, Science Direct, Cochrane, and the Frontiers in Neuroscience; this was followed by checking to see whether the paper was available in full-text. Eventually, the researcher will study the entire article to decide if it is valuable and relevant to the issue.RESULTS: CRISPR/Cas9 deletion of APOE e4, PSEN-1, and APP in induced pluripotent stem cells (iPSC’s) and g2576 mice as APP mutant models reduce tau phosphorylation and Aβ protein accumulation from neurofibrillary tangles and prevent cell death, vascular damage, and dementia. Furthermore, CRISPR/Cas9 deletion in APOE e4, PSEN-1, and APP improved neuronal cell resilience to oxidative stress and inflammation.CONCLUSION: APOE e4, PSEN-1, and APP deletion by genome editing CRISPR/Cas9 is effective to reduce tau phosphorylation and Aβ protein accumulation from neurofibrillary tangles, cell death, vascular damage, and dementia. However, further research is needed to determine the side effects and safety of its use.

30 September 2023 in Jurnal Respirasi
Verified
Journal Article
Open access
PDF file
NSNur Indah Sawitri
Nur Indah Sawitri
BRBetty Roosihermiatie
Betty Roosihermiatie
AAArga Setyo Adji
Arga Setyo Adji
SASyalomitha Claudia Stefani Angel
Syalomitha Claudia Stefani Angel
VWVira Aulia Kusuma Wardani
Vira Aulia Kusuma Wardani
RRRiami Riami
Riami Riami
Introduction: Asthmatics, especially uncontrolled asthmatics, must be vigilant during the COVID-19 pandemic to avoid major respiratory complications. This study aimed to describe these characteristics in emergency unit patients with asthma and COVID-19 at Haji General Hospital, Surabaya, an East Java referral hospital. Methods: The study gathered medical information on 160 asthma patients from March to December 2021. The collected data were related to socioeconomics, allergy history, family allergy history, and medications. Results: 160 confirmed cases of asthma occurred during COVID-19 at Haji General Hospital, Surabaya. Most adult asthma sufferers were women (59.2%), high school graduates (31.25%), housewives (21.2%), had payment method with Social Health Insurance Administration Body (BPJS) insurance (73.8 %), had a history of drug allergies (11.5%), had no family history of allergies (50.8%), and used albuterol control drugs (10.7%). Meanwhile, the majority of children with asthma were boys (53.3%), did not attend school or did not finish elementary school (33.3%), did not work (33.3%), had payment method with BPJS (73.3%), had a history of allergies to seafood and cow's milk respectively (10%), had no family history of allergies (40%), and used albuterol control drugs (16.7%). Conclusion: The proportion of asthma in the emergency unit was dominated by women over 18 years old with a high school education. Most patients were housewives and used BPJS. Many of them had a history of allergies to medications (not asthma medication), and there was no family history of allergies. Commonly used medications were albuterol to control asthma.